Metabolism of Sodium Pentosan Polysulphate in Man Measured by a New Competitive Binding Assay for Sulphated Polysaccharides – Comparison with Effects Upon Anticoagulant Activity, Lipolysis and Platelet α-Granule Proteins

Summary

Three human volunteers were injected with a range of doses of pentosan polysulphate, SP54, i.v. or s.c. A competitive binding assay (CBA) for sulphated polysaccharides was used to detect circulating SP54 after doses as low as 1 mg i.v. and a linear relationship was observed between the peak plasma concentration of SP54 measured by CBA and the administered dose. A comparison was made between the clearance of SP54 measured by CBA and its anticoagulant and lipolytic activities. SP54 was detectable by CBA after doses which caused no alteration in activated partial thromboplastin time (APTT) or anti-factor X_a activity but after which a small increase of lipase activity was measurable. After SP54 at 10 mg i.v. or 100 mg s.c. anti-factor X_a activity was 4-6 times greater than would be expected from the in vitro activity of the concentrations of SP54 measured by CBA. Like heparin and other heparin analogues, SP54 caused an increase in plasma concentrations of platelet factor 4 (PF4) without a concomitant rise in p-thromboglobulin (β-TG).

It is concluded that the newly developed CBA will provide a more sensitive means than conventional bioassays for the determination of plasma concentrations of SP54.

Keywords

Competitive binding assay - Anticoagulant - Lipase - Platelet proteins - Sulphated polysaccharides - Pentosan polysulphate

• References

• 1 MacGregor IR, Dawes J, Paton L, Pepper DS, Prowse CV, Smith M. Metabolism of sodium pentosan polysulphate in man - catabolism of iodinated derivatives. Thromb Haemostas 1984; 51: 321-325
• 2 Dawes J, Pepper DS. Catabolism of low-dose heparin in man. Thromb Res 1979; 14: 845-860
• 3 Soria C, Soria J, Rychewaert JJ, Holmer E, Caen JP. Anticoagulant activities of a pentosane poly sulphate: comparison with standard heparin and a fraction of low molecular weight heparin. Thromb Res 1980; 19: 455-463
• 4 Ryde M, Eriksson H, Tangen O. Studies on the different mechanisms by which heparin and polysulphated xylans (PZ 68) inhibit blood coagulation in man. Thromb Res 1981; 23: 435-445
• 5 Vinazzer H, Haas S, Stemberger A. Influence on the clotting mechanism of sodium pentosan polysulphate (SP54) in comparison to commercial beef lung sodium heparin. Thromb Res 1980; 20: 57-68
• 6 Bergqvist D, Nilsson IM. A sulphated polysaccharide - the effects in vivo and in vitro on the haemostatic system in healthy volunteers. Thromb Res 1981; 23: 309-315
• 7 Fischer A-M, Merton RE, Marsh NA, Williams S, Gaffney PJ, Barrowcliffe TW, Thomas DP. A comaprison of pentosan polysulphate and heparin. II: Effects of subcutaneous injection. Thromb Haemostas 1982; 47: 109-113
• 8 Dawes J, Pepper DS. A sensitive competitive binding assay for exogenous and endogenous heparins. Thromb Res 1982; 27: 387-396
• 9 Wright JF, Hunter WM. The sucrose-layering separation; a noncentrifugation system. In Immunoassays for Clinical Chemistry. Hunter W, Corrie J. (Eds) Churchill Livingstone; Edinburgh: 1983. pp 170-177
• 10 Cash JD, Gader AM, Mulder JL, Cort JH. Structure activity relations in the fibrinolytic response to vasopressin in man. Clin Sci Molec Med 1978; 54: 403-449
• 11 Yin ET, Wessler S, Butler JV. Plasma heparin: a unique practical submicrogram-sensitive assay. J Lab Clin Med 1973; 81: 298-310
• 12 Nilsson-Ehle P, Schotz NZ. A stable radioactive substrate emulsion for assay of lipoprotein lipase. J Lipid Res 1976; 17: 536-545
• 13 Bolton AE, Ludlam CA, Pepper DS, Moore S, Cash JD. A radioimmunoassay for platelet factor 4. Thromb Res 1976; 8: 51-58
• 14 Bolton AE, Ludlam CA, Moore S, Pepper DS, Cash JD. Three approaches to the radioimmunoassay of human β-thromboglobulin. Br J Haematol 1976; 33: 233-238
• 15 Thomas DP, Barrowcliffe TW, Merton RE, Stocks J, Dawes J, Pepper DS. In vivo release of anti-X_a clotting activity by a heparin analogue. Thromb Res 1980; 17: 831-840
• 16 Lane DA, Michalski R, Van Ross M, Kakkar VV. Comparison of heparin and a semi-synthetic heparin analogue A73025. 1. Kinetics of clearance from circulation of man following intravenous injection. Br J Haematol 1977; 37: 239-245
• 17 Casu B, Johnson EA, Mantovani M, Mulloy B, Oreste B, Pescador R, Prino G, Torri G, Zoppetti G. Correlation between structure, fatclearing and anticoagulant properties of heparins and heparan sulphates. Arzneim-Forsch/Drug Res 1983; 33: 135-142
• 18 de Swaart CA M, Nijmeyer B, Andersson LO, Holmer E, Verschoor L, Bouma BN, Sixma JJ. Elimination of high affinity heparin fractions and their anticoagulant and lipase activity. Blood 1984; 63: 836-842
• 19 Dawes J, Smith RC, Pepper DS. The release, distribution and clearance of human β-thromboglobulin and platelet factor 4. Thromb Res 1978; 12: 851-861
• 20 Dawes J, Pumphrey CW, McLaren KM, Prowse CV, Pepper DS. The in vivo release of human platelet factor 4 by heparin. Thromb Res 1982; 27: 65-76
• 21 Pepper DS. The role of the platelet in thrombotic disorders and the platelet release reaction. In Perspectives in Hemostasis. Fareed J, Messmore HL, Fenton JW, Brinkhous KM. (Eds) Pergamon Press; USA: 1981. pp 104-113